Rezolute price target raised to $8 from $7 at JMP Securities

JMP Securities analyst Jason Butler raised the firm’s price target on Rezolute (RZLT) to $8 from $7 and keeps an Outperform rating on the shares following Q1 results. The Phase 3 trial for ersodetug in congenital hyperinsulinism continues to enroll patients and results remain on track for 2H25, the firm noted.